Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check4 days agoChange DetectedThe product is now approved and available for sale to the public, replacing its previous status of being available only outside the clinical trial.SummaryDifference0.2%
- Check11 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the study's location.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedSeveral links related to thyroid cancer and neuroendocrine tumors have been removed, including resources from MedlinePlus and Dailymed, which may impact access to important medical information.SummaryDifference3%
- Check48 days agoChange DetectedThe website has been updated to version 2.12.2, adding numerous resources related to thyroid cancer and neuroendocrine tumors, including links to MedlinePlus, DailyMed, and clinical trial documents.SummaryDifference3%
- Check55 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.0%
Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.